BRAF V600 mutation analysis is required for treatment decision guidance in patients with distant or inoperable regional metastases and in patients with resected high-risk stage III melanoma, given the approval of BRAF and MEK inhibitors in the adjuvant setting [20]. The gene discussed is BRAF; the disease is melanoma.